393 related articles for article (PubMed ID: 28405498)
1. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Klein C; Waldhauer I; Nicolini VG; Freimoser-Grundschober A; Nayak T; Vugts DJ; Dunn C; Bolijn M; Benz J; Stihle M; Lang S; Roemmele M; Hofer T; van Puijenbroek E; Wittig D; Moser S; Ast O; Brünker P; Gorr IH; Neumann S; de Vera Mudry MC; Hinton H; Crameri F; Saro J; Evers S; Gerdes C; Bacac M; van Dongen G; Moessner E; Umaña P
Oncoimmunology; 2017; 6(3):e1277306. PubMed ID: 28405498
[TBL] [Abstract][Full Text] [Related]
2.
van Brummelen EMJ; Huisman MC; de Wit-van der Veen LJ; Nayak TK; Stokkel MPM; Mulder ER; Hoekstra OS; Vugts DJ; Van Dongen GAMS; Verheul HM; Evers S; Tessier JJL; Saro J; Schellens JHM; Menke-van der Houven van Oordt CW
Oncotarget; 2018 May; 9(37):24737-24749. PubMed ID: 29872502
[TBL] [Abstract][Full Text] [Related]
3. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
Waldhauer I; Gonzalez-Nicolini V; Freimoser-Grundschober A; Nayak TK; Fahrni L; Hosse RJ; Gerrits D; Geven EJW; Sam J; Lang S; Bommer E; Steinhart V; Husar E; Colombetti S; Van Puijenbroek E; Neubauer M; Cline JM; Garg PK; Dugan G; Cavallo F; Acuna G; Charo J; Teichgräber V; Evers S; Boerman OC; Bacac M; Moessner E; Umaña P; Klein C
MAbs; 2021; 13(1):1913791. PubMed ID: 33974508
[TBL] [Abstract][Full Text] [Related]
4. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Peters S; Angevin E; Alonso-Gordoa T; Rohrberg K; Melero I; Mellado B; Perez-Gracia JL; Tabernero J; Adessi C; Boetsch C; Watson C; Dal Porto J; Dejardin D; Del Nagro C; Nicolini V; Evers S; Klein C; Leutgeb B; Pisa P; Rossmann E; Saro J; Umana P; Charo J; Teichgräber V; Steeghs N
Clin Cancer Res; 2024 Apr; 30(8):1630-1641. PubMed ID: 38319672
[TBL] [Abstract][Full Text] [Related]
5. Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.
Ribba B; Boetsch C; Nayak T; Grimm HP; Charo J; Evers S; Klein C; Tessier J; Charoin JE; Phipps A; Pisa P; Teichgräber V
Clin Cancer Res; 2018 Jul; 24(14):3325-3333. PubMed ID: 29463551
[No Abstract] [Full Text] [Related]
6. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8
Tichet M; Wullschleger S; Chryplewicz A; Fournier N; Marcone R; Kauzlaric A; Homicsko K; Deak LC; Umaña P; Klein C; Hanahan D
Immunity; 2023 Jan; 56(1):162-179.e6. PubMed ID: 36630914
[TBL] [Abstract][Full Text] [Related]
7. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8
Codarri Deak L; Nicolini V; Hashimoto M; Karagianni M; Schwalie PC; Lauener L; Varypataki EM; Richard M; Bommer E; Sam J; Joller S; Perro M; Cremasco F; Kunz L; Yanguez E; Hüsser T; Schlenker R; Mariani M; Tosevski V; Herter S; Bacac M; Waldhauer I; Colombetti S; Gueripel X; Wullschleger S; Tichet M; Hanahan D; Kissick HT; Leclair S; Freimoser-Grundschober A; Seeber S; Teichgräber V; Ahmed R; Klein C; Umaña P
Nature; 2022 Oct; 610(7930):161-172. PubMed ID: 36171284
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
9. Improved Tumor Responses with Sequential Targeted α-Particles Followed by Interleukin 2 Immunocytokine Therapies in Treatment of CEA-Positive Breast and Colon Tumors in CEA Transgenic Mice.
Minnix M; Kujawski M; Poku E; Yazaki PJ; Wong JY; Shively JE
J Nucl Med; 2022 Dec; 63(12):1859-1864. PubMed ID: 35772959
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
Piper M; Hoen M; Darragh LB; Knitz MW; Nguyen D; Gadwa J; Durini G; Karakoc I; Grier A; Neupert B; Van Court B; Abdelazeem KNM; Yu J; Olimpo NA; Corbo S; Ross RB; Pham TT; Joshi M; Kedl RM; Saviola AJ; Amann M; Umaña P; Codarri Deak L; Klein C; D'Alessandro A; Karam SD
Cancer Cell; 2023 May; 41(5):950-969.e6. PubMed ID: 37116489
[TBL] [Abstract][Full Text] [Related]
11. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
[TBL] [Abstract][Full Text] [Related]
12. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
[TBL] [Abstract][Full Text] [Related]
13. Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.
Gadwa J; Amann M; Bickett TE; Knitz MW; Darragh LB; Piper M; Van Court B; Bukkapatnam S; Pham TT; Wang XJ; Saviola AJ; Deak LC; Umaña P; Klein C; D'Alessandro A; Karam SD
Cell Rep Med; 2023 Aug; 4(8):101150. PubMed ID: 37586327
[TBL] [Abstract][Full Text] [Related]
14. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
LaPorte KM; Hernandez R; Santos Savio A; Malek TR
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
[TBL] [Abstract][Full Text] [Related]
15. Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition.
Codarri Deak L; Hashimoto M; Umaña P; Klein C
Oncoimmunology; 2023; 12(1):2197360. PubMed ID: 37025392
[TBL] [Abstract][Full Text] [Related]
16. Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation.
Kujawski M; Sherman M; Hui S; Zuro D; Lee WH; Yazaki P; Sherman A; Szpikowska B; Chea J; Lasiewski D; Poku K; Li H; Colcher D; Wong J; Shively JE
Oncoimmunology; 2020; 9(1):1724052. PubMed ID: 32117587
[TBL] [Abstract][Full Text] [Related]
17. [
Viitanen R; Virtanen H; Liljenbäck H; Moisio O; Li XG; Nicolini V; Richard M; Klein C; Nayak T; Jalkanen S; Roivainen A
Front Immunol; 2022; 13():901693. PubMed ID: 35874707
[TBL] [Abstract][Full Text] [Related]
18. GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies.
Gellert J; Jäkel A; Danielczyk A; Goletz C; Lischke T; Flechner A; Dix L; Günzl A; Kehler P
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338686
[TBL] [Abstract][Full Text] [Related]
19. Comparison of IL-2-antibody to IL-2-Fc with or without stereotactic radiation therapy in CEA immunocompetent mice with CEA positive tumors.
Williams L; Li L; Yazaki PJ; Wong P; Hong T; Poku EK; Hui S; Ghimire H; Shively JE; Kujawski M
Cancer Med; 2024 Feb; 13(3):e6909. PubMed ID: 38317590
[TBL] [Abstract][Full Text] [Related]
20. Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy.
Jung K; Yoo S; Kim JE; Kim W; Kim YS
Front Immunol; 2022; 13():1034774. PubMed ID: 36405748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
